NCT03271333Completed
Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma.
Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma and Analysis of Associated Factors.
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
Diffuse infiltrating pneumonia (DIP) is a severe complication of systemic sclerosis and one of the leading cause of death in this condition. The main objective of this study is to prospectively describe the evolution of DIP overtime and to find prognosis factors.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 56 (actual)
- First submitted
- 31 Aug 2017
- Start date
- 10 Apr 2018
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University Hospital, Lille
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT03271333
What you commit to
- Study type: Observational
- Participants enrolled: 56
- From 10 Apr 2018 to the primary completion date, 31 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- infection
- other lung diseases
Other
- non French native
Who the study is looking for
- systemic sclerosis
- Diffuse Infiltrating Pneumonia
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Claude Huriez, CHU Coordinator of this site? Confirm its status | Lille | France | Unknown status |
| AH-HP, Hôpital Saint Antoine Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.